Scientific Reports (Apr 2021)

Flow virometry for process monitoring of live virus vaccines-lessons learned from ERVEBO

  • Geoffri Ricci,
  • Kevin Minsker,
  • Austin Kapish,
  • James Osborn,
  • Sha Ha,
  • Joseph Davide,
  • Joseph P. Califano,
  • Darrell Sehlin,
  • Richard R. Rustandi,
  • Lawrence W. Dick,
  • Josef Vlasak,
  • Timothy D. Culp,
  • Andreas Baudy,
  • Edward Bell,
  • Malini Mukherjee

DOI
https://doi.org/10.1038/s41598-021-86688-z
Journal volume & issue
Vol. 11, no. 1
pp. 1 – 12

Abstract

Read online

Abstract Direct at line monitoring of live virus particles in commercial manufacturing of vaccines is challenging due to their small size. Detection of malformed or damaged virions with reduced potency is rate-limited by release potency assays with long turnaround times. Thus, preempting batch failures caused by out of specification potency results is almost impossible. Much needed are in-process tools that can monitor and detect compromised viral particles in live-virus vaccines (LVVs) manufacturing based on changes in their biophysical properties to provide timely measures to rectify process stresses leading to such damage. Using ERVEBO, MSD’s Ebola virus vaccine as an example, here we describe a flow virometry assay that can quickly detect damaged virus particles and provide mechanistic insight into process parameters contributing to the damage. Furthermore, we describe a 24-h high throughput infectivity assay that can be used to correlate damaged particles directly to loss in viral infectivity (potency) in-process. Collectively, we provide a set of innovative tools to enable rapid process development, process monitoring, and control strategy implementation in large scale LVV manufacturing.